Nature reviews. Drug discovery

Keyphrases

Publications

volume 23, number 7, 2024

Rami Al-Horani, Thomas Chui, Bashar Hamad
The pipeline and market for psoriasis drugs. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Designing reversible anticoagulants. Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments. Nature reviews. Drug discovery 23 (7) (2024)
Katie Kingwell
Expanding the psychedelic toolkit. Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
Chromatin-targeted drug discovery at "a very special moment". Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
FDA approves mRNA-based RSV vaccine. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Reducing seizures with senolytic drugs. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Reducing seizures with senolytic drugs. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Predicting ligand-protein interactions. Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
Extracellular targeted protein degrader removes antibodies in first test in humans. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Assessing accuracy of AlphaFold2. Nature reviews. Drug discovery 23 (7) (2024)
M Teresa Villanueva
RNA delivery heats up cold tumours. Nature reviews. Drug discovery 23 (7) (2024)
Isobel Leake
A route to small-molecule Lp(a) inhibitors for heart disease. Nature reviews. Drug discovery 23 (7) (2024)
Francisco Ramírez-Valle, Joseph C Maranville, Sophie Roy, Robert M Plenge
Sequential immunotherapy: towards cures for autoimmunity. Nature reviews. Drug discovery 23 (7) (2024)
Francisco Ramírez-Valle, Joseph C Maranville, Sophie Roy, Robert M Plenge
Sequential immunotherapy: towards cures for autoimmunity. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Dual-acting GLP-1 conjugate enhances weight loss. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Predicting ligand-protein interactions. Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer. Nature reviews. Drug discovery 23 (7) (2024)
Richard J Brennan, Stephen Jenkinson, Andrew J Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott W Mittlestadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James M Vergis, Jean-Pierre Valentin
The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Designing reversible anticoagulants. Nature reviews. Drug discovery 23 (7) (2024)
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin Biroulet
Navigating the complexities of drug development for inflammatory bowel disease. Nature reviews. Drug discovery 23 (7) (2024)
Katharine Wright, Willyanne DeCormier Plosky, Hayat R Ahmed, Sarah A White, Barbara E Bierer
First, do no harm: a global perspective on diversity and inclusion in clinical trials. Nature reviews. Drug discovery 23 (7) (2024)
Richard J Brennan, Stephen Jenkinson, Andrew J Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott W Mittlestadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James M Vergis, Jean-Pierre Valentin
The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nature reviews. Drug discovery 23 (7) (2024)
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin Biroulet
Navigating the complexities of drug development for inflammatory bowel disease. Nature reviews. Drug discovery 23 (7) (2024)
Katharine Wright, Willyanne DeCormier Plosky, Hayat R Ahmed, Sarah A White, Barbara E Bierer
First, do no harm: a global perspective on diversity and inclusion in clinical trials. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Assessing accuracy of AlphaFold2. Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
FDA approves mRNA-based RSV vaccine. Nature reviews. Drug discovery 23 (7) (2024)
Sarah Crunkhorn
Dual-acting GLP-1 conjugate enhances weight loss. Nature reviews. Drug discovery 23 (7) (2024)
Asher Mullard
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer. Nature reviews. Drug discovery 23 (7) (2024)
Rami Al-Horani, Thomas Chui, Bashar Hamad
The pipeline and market for psoriasis drugs. Nature reviews. Drug discovery 23 (7) (2024)

volume 23, number 8, 2024

Asher Mullard
FDA approves 21-valent pneumococcal vaccine. Nature reviews. Drug discovery 23 (8) (2024)
Paul Verdin
FDA new drug approvals in Q2 2024. Nature reviews. Drug discovery 23 (8) (2024)
Asher Mullard
FDA approves first telomerase inhibitor. Nature reviews. Drug discovery 23 (8) (2024)
Sarah Crunkhorn
Discovering CFTR modulators. Nature reviews. Drug discovery 23 (8) (2024)
Asher Mullard
Gene therapies start the climb from rare disease base camps to common disease peaks. Nature reviews. Drug discovery 23 (8) (2024)
Christophe Glorieux, Shihua Liu, Dunyaporn Trachootham, Peng Huang
Targeting ROS in cancer: rationale and strategies. Nature reviews. Drug discovery 23 (8) (2024)
Ningqiang Gong, Mohamad-Gabriel Alameh, Rakan El-Mayta, Lulu Xue, Drew Weissman, Michael J Mitchell
Enhancing in situ cancer vaccines using delivery technologies. Nature reviews. Drug discovery 23 (8) (2024)
Katie Kingwell
Rebalancing calcium in Alzheimer disease. Nature reviews. Drug discovery 23 (8) (2024)
Sarah Crunkhorn
Machine learning identifies AMPs. Nature reviews. Drug discovery 23 (8) (2024)
Sarah Crunkhorn
ETS2 drives IBD. Nature reviews. Drug discovery 23 (8) (2024)
Asher Mullard
FDA approves third anti-amyloid antibody for Alzheimer disease. Nature reviews. Drug discovery 23 (8) (2024)
Terry Kenakin
Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition. Nature reviews. Drug discovery 23 (8) (2024)
Sarah Crunkhorn
A selective microbiome-sparing antibiotic. Nature reviews. Drug discovery 23 (8) (2024)
Yvonne Bordon
CAR T cells take to the airways. Nature reviews. Drug discovery 23 (8) (2024)
Paul D Pang, Syed Mukhtar Ahmed, Masataka Nishiga, Norman L Stockbridge, Joseph C Wu
Tackling the challenges of new approach methods for predicting drug effects from model systems. Nature reviews. Drug discovery 23 (8) (2024)
Sarah Crunkhorn
Discovering CFTR modulators. Nature reviews. Drug discovery 23 (8) (2024)
M Teresa Villanueva
A rush of CRISPR to the lungs. Nature reviews. Drug discovery 23 (8) (2024)
Ken Garber
Menin inhibitors seek to debut as newest targeted therapy for leukaemia. Nature reviews. Drug discovery 23 (8) (2024)
Asher Mullard
FDA approves first telomerase inhibitor. Nature reviews. Drug discovery 23 (8) (2024)
Patrick Flynn, Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu
The antibody-drug conjugate landscape. Nature reviews. Drug discovery 23 (8) (2024)